The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.




The University of Alabama at Birmingham – $100,000

Amount
$100,000.00
Date
December 2023

Intranasal Delivery of Targeting Nanotherapeutics for DIPG

Funding of PBTCF 2023 - $25,000

Amount
$25,000.00
Date
December 2023

Children's Cancer Institute – $181,736 USD, $281,691 AUD

Amount
$181,736.00
Date
November 2023

Targeting post-translational protein modification to halt Diffuse Intrinsic Pontine Glioma tumorgenicity

Memorial Sloan Kettering Cancer Center – $100,000

Amount
$100,000.00
Date
November 2023

CSF Cell-free Tumor DNA (CSF cfDNA) Liquid Biopsies for Pediatric, Adolescent, and Young Adult Patients with Primary Brain Tumors

University of Colorado Denver – $200,000

Amount
$200,000.00
Date
November 2023

Preclinical assessment of efficacy and specificity of logic-gated CAR-T cell therapy in Diffuse Intrinsic Pontine Glioma

SIOPe DIPG/DMG Registry – $715,852 USD, € 643,014

Amount
$715,852.00
Date
November 2023

Renewal of the European DIPG/DMG Registry

Cincinnati Children's Hospital – $200,000

Amount
$200,000.00
Date
November 2023

Targeting diffuse midline gliomas with innovative T cell immunotherapy

Cincinnati Children's Hospital – $50,000

Amount
$50,000.00
Date
May 2023

Exploring Novel Targets In DIPG

University Medicine Göttingen – $50,000

Amount
$50,000.00
Date
May 2023

Starve the monster: Multi-metabolic treatment strategies for H3.3K27M-mutant DIPG/DMG

Funding of PBTCF 2023 - $25,000

Amount
$25,000.00
Date
January 2023

University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
November 2022

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma

Erasmus University Medical Center – $432,354

Amount
$432,354.00
Date
November 2022

Development and optimization of targeted radiopharmaceutical therapies for pediatric brain tumors; a world-first translational study. Acronym: TARGET-FIRST

Cincinnati Children's Hospital Medical Center – $60,000

Amount
$60,000.00
Date
November 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital Medical Center – $153,867

Amount
$153,867.00
Date
November 2022

Combining innovative proton radiotherapy with targeted and immune therapies to treat DMG/DIPG

Hunter Medical Research Institute – $232,932

Amount
$232,932.00
Date
November 2022

Enhancing the recruitment of tumor infiltrating lymphocytes to improve responses to DMG therapies